Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $34.83.

Several research firms recently commented on VIR. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, January 31st. Leerink Partners lifted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. JPMorgan Chase & Co. raised their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Barclays dropped their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th.

Vir Biotechnology Stock Up 1.8 %

VIR stock opened at $10.23 on Friday. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -2.61 and a beta of 0.63. Vir Biotechnology has a twelve month low of $6.56 and a twelve month high of $14.45. The business’s fifty day simple moving average is $8.99 and its two-hundred day simple moving average is $8.52.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 15.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its stake in Vir Biotechnology by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,987 shares of the company’s stock valued at $436,000 after purchasing an additional 3,605 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of Vir Biotechnology by 27.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 57,446 shares of the company’s stock valued at $430,000 after acquiring an additional 12,511 shares during the period. nVerses Capital LLC purchased a new position in Vir Biotechnology in the 3rd quarter worth $56,000. Blue Trust Inc. lifted its position in Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after acquiring an additional 2,351 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Vir Biotechnology by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,280 shares of the company’s stock valued at $197,000 after purchasing an additional 10,294 shares during the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).